Vertex Pharmaceuticals Inc
VRTX387.150USD
-4.210-1.08%
Handelsschluss 09/17, 16:00（ET）Kurse um 15 Minuten verzögert
99.22BMarktkapitalisierung
27.28KGV TTM
mehr Informationen über Vertex Pharmaceuticals Inc Unternehmen
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.
Unternehmensinformationen
BörsenkürzelVRTX
Name des UnternehmensVertex Pharmaceuticals Inc
IPO-datumJul 24, 1991
CEODr. Reshma Kewalramani
Anzahl der mitarbeiter6100
WertpapierartOrdinary Share
GeschäftsjahresendeJul 24
Addresse50 Northern Avenue
StadtBOSTON
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02210
Telefon16173416393
Websitehttps://www.vrtx.com/
BörsenkürzelVRTX
IPO-datumJul 24, 1991
CEODr. Reshma Kewalramani
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
51.81K
+23.92%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
45.00K
+12.50%
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
17.61K
+5.74%
Mr. Duncan Mckechnie
Mr. Duncan Mckechnie
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
16.13K
--
Mr. Lloyd A. Carney
Mr. Lloyd A. Carney
Independent Director
Independent Director
7.12K
+12.60%
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Independent Director
Independent Director
4.57K
-5.51%
Ms. Jennifer J. Schneider
Ms. Jennifer J. Schneider
Independent Director
Independent Director
1.72K
+86.33%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
51.81K
+23.92%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
45.00K
+12.50%
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
17.61K
+5.74%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
TRIKAFTA
2.54B
91.86%
Other product revenues
156.60M
5.67%
ALYFTREK
53.90M
1.95%
CASGEVY
14.20M
0.51%
Nach RegionUSD
Name
Umsatz
Anteil
United States
1.65B
59.91%
Europe
826.60M
29.95%
Other
280.10M
10.15%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
TRIKAFTA
2.54B
91.86%
Other product revenues
156.60M
5.67%
ALYFTREK
53.90M
1.95%
CASGEVY
14.20M
0.51%
Aktionärsstatistik
Aktualisiert: Sun, Aug 17
Aktualisiert: Sun, Aug 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Capital World Investors
11.21%
The Vanguard Group, Inc.
9.31%
Capital Research Global Investors
6.28%
BlackRock Institutional Trust Company, N.A.
5.52%
State Street Global Advisors (US)
4.59%
Andere
63.09%
Aktionäre
Aktionäre
Anteil
Capital World Investors
11.21%
The Vanguard Group, Inc.
9.31%
Capital Research Global Investors
6.28%
BlackRock Institutional Trust Company, N.A.
5.52%
State Street Global Advisors (US)
4.59%
Andere
63.09%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
60.29%
Investment Advisor/Hedge Fund
28.71%
Research Firm
2.55%
Pension Fund
2.27%
Bank and Trust
1.99%
Sovereign Wealth Fund
1.49%
Hedge Fund
0.69%
Individual Investor
0.14%
Insurance Company
0.09%
Andere
1.76%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
2933
252.71M
98.56%
+2.47M
2025Q1
2977
252.24M
98.22%
-39.54K
2024Q4
2877
248.76M
96.87%
-2.25M
2024Q3
2786
247.87M
96.18%
-4.19M
2024Q2
2747
248.36M
96.27%
-4.14M
2024Q1
2680
247.63M
95.87%
-4.48M
2023Q4
2608
247.92M
96.20%
-4.51M
2023Q3
2477
248.64M
96.45%
-6.19M
2023Q2
2488
248.89M
96.55%
-7.11M
2023Q1
2468
250.11M
97.13%
-4.74M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Capital World Investors
28.53M
11.11%
+207.61K
+0.73%
Mar 31, 2025
The Vanguard Group, Inc.
23.38M
9.1%
+232.41K
+1.00%
Mar 31, 2025
Capital Research Global Investors
14.54M
5.66%
+4.11M
+39.38%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
14.00M
5.45%
-330.35K
-2.31%
Mar 31, 2025
State Street Global Advisors (US)
11.79M
4.59%
-190.75K
-1.59%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.62M
2.97%
-1.49M
-16.32%
Mar 31, 2025
Jennison Associates LLC
5.06M
1.97%
+744.68K
+17.25%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.76M
2.24%
+113.52K
+2.01%
Mar 31, 2025
Invesco Capital Management (QQQ Trust)
5.31M
2.07%
-20.76K
-0.39%
Jun 30, 2025
Wellington Management Company, LLP
5.45M
2.12%
-461.34K
-7.80%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Sep 2
Aktualisiert: Tue, Sep 2
Name
Anteil
VanEck Biotech ETF
10.62%
iShares Biotechnology ETF
6.92%
First Trust NYSE Arca Biotechnology Index Fund
3.35%
SPDR S&P Biotech ETF
2.44%
iShares U.S. Healthcare ETF
2.39%
Health Care Select Sector SPDR Fund
2.34%
Fidelity MSCI Health Care Index ETF
2.06%
First Trust NASDAQ-100 Ex-Technology Sector Index Fund
1.81%
Capital Group Core Equity ETF
1.77%
iShares Global Healthcare ETF
1.68%
Mehr Anzeigen
VanEck Biotech ETF
Anteil10.62%
iShares Biotechnology ETF
Anteil6.92%
First Trust NYSE Arca Biotechnology Index Fund
Anteil3.35%
SPDR S&P Biotech ETF
Anteil2.44%
iShares U.S. Healthcare ETF
Anteil2.39%
Health Care Select Sector SPDR Fund
Anteil2.34%
Fidelity MSCI Health Care Index ETF
Anteil2.06%
First Trust NASDAQ-100 Ex-Technology Sector Index Fund
Anteil1.81%
Capital Group Core Equity ETF
Anteil1.77%
iShares Global Healthcare ETF
Anteil1.68%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
